Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy

Yang Gun Suh, Eun Jung Lee, Hyejung Cha, Seung Hyun Yang, Jinsil Seong

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: Hepatocellular carcinoma (HCC) is a highly vascularized tumor. In this study, we investigated the prognostic and predictive values of proangiogenic factors in HCC patients receiving radiotherapy.

Methods: Between September 2008 and December 2009, a total of 50 patients treated with radiotherapy were prospectively enrolled in this study. Serum and urine samples were collected <1 week before and after radiotherapy.

Results: After completion of radiotherapy, serum vascular endothelial growth factor (VEGF)/platelet (Plt) levels were significantly increased (p < 0.01). Patients who experienced hepatic tumor recurrence outside the radiation field showed higher VEGF-A/Plt levels before and after radiotherapy than patients who did not (p = 0.04), whereas patients who had hepatic tumor recurrence inside the radiation field showed significantly higher matrix metalloproteinase (MMP)-2 levels after radiotherapy (p = 0.04). On multivariate analyses, a high level of either VEGF/Plt or MMP-2 (≥ median) before radiotherapy was a significant independent prognostic factor for a worse progression-free survival (p = 0.04).

Conclusions: In HCC patients receiving radiotherapy, levels of VEGF/Plt and MMP-2 before radiotherapy can be useful to predict treatment outcome. This study also suggests the necessity of anti-angiogenic therapy, such as sorafenib, since radiotherapy increases VEGF/Plt levels, and higher levels of VEGF/Plt are associated with a poor outcome.

Original languageEnglish
Pages (from-to)725-732
Number of pages8
JournalDigestive Diseases
Volume32
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Matrix Metalloproteinase 2
Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Radiotherapy
Blood Platelets
Radiation
Recurrence
Neoplasms
Liver
Serum
Disease-Free Survival
Multivariate Analysis
Urine

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{c10f0bb3691c4eda9b79f0ace80a605d,
title = "Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy",
abstract = "Objectives: Hepatocellular carcinoma (HCC) is a highly vascularized tumor. In this study, we investigated the prognostic and predictive values of proangiogenic factors in HCC patients receiving radiotherapy.Methods: Between September 2008 and December 2009, a total of 50 patients treated with radiotherapy were prospectively enrolled in this study. Serum and urine samples were collected <1 week before and after radiotherapy.Results: After completion of radiotherapy, serum vascular endothelial growth factor (VEGF)/platelet (Plt) levels were significantly increased (p < 0.01). Patients who experienced hepatic tumor recurrence outside the radiation field showed higher VEGF-A/Plt levels before and after radiotherapy than patients who did not (p = 0.04), whereas patients who had hepatic tumor recurrence inside the radiation field showed significantly higher matrix metalloproteinase (MMP)-2 levels after radiotherapy (p = 0.04). On multivariate analyses, a high level of either VEGF/Plt or MMP-2 (≥ median) before radiotherapy was a significant independent prognostic factor for a worse progression-free survival (p = 0.04).Conclusions: In HCC patients receiving radiotherapy, levels of VEGF/Plt and MMP-2 before radiotherapy can be useful to predict treatment outcome. This study also suggests the necessity of anti-angiogenic therapy, such as sorafenib, since radiotherapy increases VEGF/Plt levels, and higher levels of VEGF/Plt are associated with a poor outcome.",
author = "Suh, {Yang Gun} and Lee, {Eun Jung} and Hyejung Cha and Yang, {Seung Hyun} and Jinsil Seong",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000368010",
language = "English",
volume = "32",
pages = "725--732",
journal = "Digestive Diseases",
issn = "0257-2753",
publisher = "S. Karger AG",
number = "6",

}

Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy. / Suh, Yang Gun; Lee, Eun Jung; Cha, Hyejung; Yang, Seung Hyun; Seong, Jinsil.

In: Digestive Diseases, Vol. 32, No. 6, 01.01.2014, p. 725-732.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic values of vascular endothelial growth factor and matrix metalloproteinase-2 in hepatocellular carcinoma after radiotherapy

AU - Suh, Yang Gun

AU - Lee, Eun Jung

AU - Cha, Hyejung

AU - Yang, Seung Hyun

AU - Seong, Jinsil

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: Hepatocellular carcinoma (HCC) is a highly vascularized tumor. In this study, we investigated the prognostic and predictive values of proangiogenic factors in HCC patients receiving radiotherapy.Methods: Between September 2008 and December 2009, a total of 50 patients treated with radiotherapy were prospectively enrolled in this study. Serum and urine samples were collected <1 week before and after radiotherapy.Results: After completion of radiotherapy, serum vascular endothelial growth factor (VEGF)/platelet (Plt) levels were significantly increased (p < 0.01). Patients who experienced hepatic tumor recurrence outside the radiation field showed higher VEGF-A/Plt levels before and after radiotherapy than patients who did not (p = 0.04), whereas patients who had hepatic tumor recurrence inside the radiation field showed significantly higher matrix metalloproteinase (MMP)-2 levels after radiotherapy (p = 0.04). On multivariate analyses, a high level of either VEGF/Plt or MMP-2 (≥ median) before radiotherapy was a significant independent prognostic factor for a worse progression-free survival (p = 0.04).Conclusions: In HCC patients receiving radiotherapy, levels of VEGF/Plt and MMP-2 before radiotherapy can be useful to predict treatment outcome. This study also suggests the necessity of anti-angiogenic therapy, such as sorafenib, since radiotherapy increases VEGF/Plt levels, and higher levels of VEGF/Plt are associated with a poor outcome.

AB - Objectives: Hepatocellular carcinoma (HCC) is a highly vascularized tumor. In this study, we investigated the prognostic and predictive values of proangiogenic factors in HCC patients receiving radiotherapy.Methods: Between September 2008 and December 2009, a total of 50 patients treated with radiotherapy were prospectively enrolled in this study. Serum and urine samples were collected <1 week before and after radiotherapy.Results: After completion of radiotherapy, serum vascular endothelial growth factor (VEGF)/platelet (Plt) levels were significantly increased (p < 0.01). Patients who experienced hepatic tumor recurrence outside the radiation field showed higher VEGF-A/Plt levels before and after radiotherapy than patients who did not (p = 0.04), whereas patients who had hepatic tumor recurrence inside the radiation field showed significantly higher matrix metalloproteinase (MMP)-2 levels after radiotherapy (p = 0.04). On multivariate analyses, a high level of either VEGF/Plt or MMP-2 (≥ median) before radiotherapy was a significant independent prognostic factor for a worse progression-free survival (p = 0.04).Conclusions: In HCC patients receiving radiotherapy, levels of VEGF/Plt and MMP-2 before radiotherapy can be useful to predict treatment outcome. This study also suggests the necessity of anti-angiogenic therapy, such as sorafenib, since radiotherapy increases VEGF/Plt levels, and higher levels of VEGF/Plt are associated with a poor outcome.

UR - http://www.scopus.com/inward/record.url?scp=84910658487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910658487&partnerID=8YFLogxK

U2 - 10.1159/000368010

DO - 10.1159/000368010

M3 - Article

VL - 32

SP - 725

EP - 732

JO - Digestive Diseases

JF - Digestive Diseases

SN - 0257-2753

IS - 6

ER -